Navigation Links
New Diagnostic Biomarker Test Shows Promise in Monitoring Ovarian Cancer
Date:7/22/2009

ce president, research and development, Abbott Diagnostics. "HE4 represents an important advancement in monitoring these pelvic masses."

Fujirebio Diagnostics, Inc. and Abbott have signed a license agreement to develop this new ovarian cancer marker for use on Abbott's automated ARCHITECT(R) diagnostic analyzers. A manual form of the HE4 test has been approved by the Food and Drug Association (FDA) as an aid in monitoring recurrence or progressive disease in patients with EOC and is CE marked for use within the European Union as an aid in estimating the risk of epithelial ovarian cancer in premenopausal and postmenopausal women.

About Ovarian Cancer

Ovarian cancer is the leading cause of death from gynecologic cancers in the United States and the fifth-leading cause of cancer death in women. An estimated one in 72 women will develop ovarian cancer in their lifetimes. It accounts for 31 percent of cancers of the female genital organs. Women who are postmenopausal are at the greatest risk for ovarian cancer.

About Abbott Diagnostics

Abbott Diagnostics is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, blood banks, physician offices and clinics. With more than 69,000 institutional customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnostics from an art to a science through the company's commitment to improving patient care and lowering overall costs. The history of Abbott Diagnostics is filled with examples of first-of-a-kind products and significant technological advancements, including the development of the very first diagnostic test to detect HIV.

About Abbott

Abbott (NYSE: '/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. Quest Diagnostics to Speak at the Bear Stearns Healthcare Conference
4. Pathway Diagnostics Announces Commercial Availability of SensiTrop(TM) HIV Co-receptor Tropism Assay
5. Hypertension Diagnostics Announces Fiscal Year 2007 Results
6. Foundation Venture Capital Group, LLC Invests in Start Up Committed to Breast Cancer Diagnostics
7. Meretek Diagnostics and Otsuka America Pharmaceutical, Inc. Announce Completion of Merger
8. Siemens Medical Solutions Diagnostics Announces the Release of the Rapidlab 1200 Series Version 2.0 Software
9. Aloka to Unveil New ProSound Diagnostic Ultrasound System at the 17th World Congress on Ultrasound in Obstetrics and Gynecology, 7th to 11th of October 2007 in Florence, Italy
10. New peritoneal dialysis diagnostic discovered
11. Virginia G. Piper Charitable Trust and Flinn Foundation launch molecular diagnostics initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... How well patients recover from cancer surgery may ... and the operations themselves. Family conflicts and other ... complications, a Mayo Clinic study has found. Addressing ... patients, stress, speed their recoveries and save health ... looked at colon cancer patients, and found that ...
(Date:9/2/2014)... suggests that the key to more youthful immune function ... report published in the Journal of Leukocyte ... lungs of old mice had different responses to ... these changes were reversed by ibuprofen. , "Inflammation in ... said Joanne Turner, Ph.D., a researcher involved in the ...
(Date:9/2/2014)... 02, 2014 According to a ... the leading global authority in medical device market ... is expected to grow to over €2 billion ... increase in the number of procedures for the ... This market includes TURP devices, laser BPH devices, ...
(Date:9/2/2014)... 02, 2014 Nanomedicine is essentially ... diagnosing, treating and/or prevention of diseases and infections. ... cardiovascular, neurological, and oncology diseases. , Nanomedicine ... to various nanoparticles, their medical usages, and their ... considerable scope for research in this domain, and ...
(Date:9/2/2014)... On Saturday, September 6, 2014, The Concilio will present ... vida! Get Up! Get Moving!®. This event promotes Hispanic family ... for people of all ages and all sizes. The event, ... held at Kiest Park Recreation Center, 3080 S. Hampton Road, ... “Since 2007, we have partnered with National Alliance for Hispanic ...
Breaking Medicine News(10 mins):Health News:Family conflicts, other non-physical worries before cancer surgery raise patients' complication risk 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 2Health News:European Urological Device Market Is Expected to Grow to over €2 billion by 2020: Led by Coloplast, Wellspect HealthCare, Teleflex, C. R. Bard and Olympus 3Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:The Concilio Presents Eighth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4
... Will Continue to be Used in Early ... from Decision Resources, WALTHAM, Mass., Oct. ... leading research and advisory firms focusing on ... is currently the leading biologic for Crohn,s ...
... 1, 2008 at this year,s liver ... SAN FRANCISCO, Oct. 27 Researchers analyzed 43,497,patients ... 22,863 adults,who received transplantation to determine the best time ... caused by differences in donor type was vastly offset ...
... 27 ReachMD XM 157 announces a new,"Medical ... receptor,antagonist and its effects on management of euvolemic ... XM 157, the first and only network for ... the Tide Against,Hyponatremia" four times a day October ...
... NORWALK, Conn., Oct. 27 Maclaren USA Inc.,announces the ... Chief Operation Officer., "Maclaren,s growth has been extraordinary ... our new from-birth transport system, the Grand Tour(TM),LX, is ... proven themselves to be exceptional leaders in their field. ...
... has donated a portable Automatic External Defibrillator (AED) to Habitat ... ... Newtown, Pennsylvania (PRWEB) October 27, 2008 -- HeartSine Technologies, ... donated a portable Automatic External Defibrillator (AED) to Habitat for ...
... reduced inflammation, cholesterol and belly fat , , SUNDAY, Oct. ... diet." , New research ties eating tart cherries ... weight and fat -- all major risk factors for ... presented by University of Michigan researchers at the American ...
Cached Medicine News:Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 2Health News:Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease 3Health News:Early Liver Transplantation Regardless of Donor Type Increases Long-term Survival 2Health News:ReachMD XM 157 Announces Medical Information Feature on Treatment Options for Management of Hyponatremia 2Health News:ReachMD XM 157 Announces Medical Information Feature on Treatment Options for Management of Hyponatremia 3Health News:Maclaren Appoints New President and New Chief Operation Officer 2Health News:HeartSine Portable Defibrillator Donation Brings Added Safety to Habitat for Humanity of Charlotte ReStore Location 2Health News:Cherry-Enriched Diet Cut Heart Risks in Rats 2
(Date:9/2/2014)... -- Actavis plc (NYSE: ACT ) today ... has accepted for filing Actavis, New Drug Application (NDA) ... diarrhea and abdominal pain in men and women with ... eluxadoline has been granted priority review status by the ... "The NDA filing of eluxadoline marks an important ...
(Date:9/2/2014)... CITY, Calif. , Sept. 2, 2014  Abaxis, ... company manufacturing point-of-care blood instrumentation and consumables to the ... Clint Severson , Chairman and Chief Executive Officer, will ... Wednesday, September 10, 2014 at 10:20 a.m. ET. The ... York in New York City . ...
(Date:9/2/2014)... SAN DIEGO , Sept. 2, 2014   Mast Therapeutics, ... Executive Officer, Brian M. Culley , will present at the ... Tuesday, September 9, 2014 at 2:55 p.m. Eastern time in the ... New York . Interested parties can ... Therapeutics web site at www.masttherapeutics.com . An archived presentation will ...
Breaking Medicine Technology:Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 2Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 3Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline 4Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th 2Mast Therapeutics To Present At The Rodman And Renshaw 16th Annual Global Investment Conference On September 9th 3
... , WASHINGTON, Dec. 14 ... counsel on global and domestic communications and issues management, ... PositiveID Corporation (Nasdaq: PSID ) to serve as ... will conduct media relations for PositiveID,s corporate communications and ...
... , NEW HAVEN, Conn., ,Dec. 14 /PRNewswire-FirstCall/ ... today announced that it had received a complete response ... related to its New Drug Application ("NDA") for Onrigin(TM) ... indicates that the FDA cannot approve the Company,s NDA ...
Cached Medicine Technology:Gibraltar Associates Named Agency of Record for Health Information and Diagnostic Provider PositiveID Corporation 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 2Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: